Anti-CXCR2 and anti-PD-1 have been shown to synergistically reduce tumor mass and enhance CD4+ and CD8+ T-cell infiltration.136 Three CXCR1/2 antagonists (SX-682, reparixin, and MK-7123) are being evaluated in clinical trials as adjunctive cancer therapies. Here, CD4 is linked to neoplasm.